Loading...
Complement Inhibitor Eculizumab in Atypical Hemolytic Uremic Syndrome
Background and objectives: Atypical hemolytic uremic syndrome (aHUS) is associated with a congenital or acquired dysregulation of the complement alternative pathway that leads to continuous complement activation on host cells causing inflammation and damage. Eculizumab, a humanized mAb against compl...
Na minha lista:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
American Society of Nephrology
2009
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2723971/ https://ncbi.nlm.nih.gov/pubmed/19556379 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2215/CJN.01090209 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|